Prognostic Test for Age-Related Macular Degeneration



October 18, 2011

  • Share
  • Dr. Preveen Ramamoorthy founded the Molecular Diagnostics department at National Jewish Health, Denver in 2007. Currently, he directs the translation of biomarkers into molecular diagnostic tests at the Advanced Diagnostic Laboratories at National Jewish Health. His laboratory has launched numerous rapid diagnostic, prognostic and companion diagnostic tests and is serving patients and physicians at National Jewish Health and the U.S.A. Dr. Ramamoorthy is passionately interested in the development of genome based diagnostic tests, integrating them into personalized medicine clinical programs and enabling physicians and patients to prevent, manage and treat diseases. Dr. Ramamoorthy serves on the advisory boards of TATAA Biocenter, PrognosDx, Genome International Corporation and Global Chest Initiatives. Prior to joining National Jewish Health Dr. Ramamoorthy was involved in the development of viral vaccines, cancer vaccines and monoclonal antibodies at MedImmune. Dr. Ramamoorthy completed his post-doctoral fellowship at Walter Reed Army Institute of Research, Silver Spring in genomics and molecular diagnostics. During his Ph.D at Clemson University Dr. Ramamoorthy co-invented a prolactin receptor antagonist, a molecular therapeutic drug for breast cancer. Dr. Ramamoorthy obtained his Master’s in Medical Microbiology at the University of Madras before he embarked upon his Ph.D program at Clemson University.

    GenomicsImmunologyMass SpectrometryPersonalized Medicine

    Keep up to date with all your favourite videos and channels.

    Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.